Cath lab costs in patients undergoing percutaneous coronary angioplasty — detailed analysis of consecutive procedures

Dziki, Beata; Miechowicz, Izabela; Iwachów, Piotr; Kuzemczak, Michał; Kałmucki, Piotr; Szyszka, Andrzej; Baszko, Artur; Siminiak, Tomasz

doi:10.5603/kp.a2017.0098

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to various data, they cost the European economy 160 bn to 210 bn EUR a year (Paczkowska et al, 2014). Due to the importance of this problem, there are a number of papers discussing the cost of CVD in different European countries available (Dziki et al, 2017). These studies used both a top-down and a bottom-up approach to assess the resources used.…”

Section: Discussionmentioning

confidence: 99%

Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years

et al. 2020

View full text Add to dashboard Cite

Background: Cardiovascular diseases are associated with growing public and private expenditure on healthcare regardless geographic region. Therefore, it is necessary to accurately estimate the overall societal costs-both direct and indirect expenses from the perspective of patients, caregivers and employers. Research Design: The aim of this paper is to determine the direct and indirect costs related to cardiovascular diseases in Poland from 2015 to 2017. All costs are estimated based on data available in the public domain and obtained from the major Polish institutions. Indirect costs were calculated using a modified human capital approach. Results: The financial burden of cardiovascular diseases in Poland is significant. This study revealed that total costs (direct and indirect) of cardiovascular diseases, for 2015-2017, range from 34.9 bn PLN (8.2 bn EUR) to over 40.9 bn PLN (9.6 bn EUR). Total direct cost and indirect costs were approximately 6.1 bn PLN (1.4 bn EUR) (16%) and 31.3 bn PLN (7.3 bn EUR) (84%), respectively. Conclusion: Collectively, the estimated direct and indirect cost of cardiovascular diseases provide a useful input for economic impact assessments of public health programs and health technology analyses.

show abstract

Section: Discussionmentioning

confidence: 99%

Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Data presented in these studies again demonstrate reduced rates of complications as the primary driver rather than procedural cost differences. For example, in a small trial, Dziki et al [62] demonstrated comparable procedural cath lab costs when comparing TRI to TFI. Finally, it is noteworthy that the recent, large study [61] from England again demonstrated that the TRI costs are even lower in STEMI patients (348£) as compared to stable CAD patients (153£)-a finding that is concordant with the Safley et al [54] and Amin et al [55] studies from the US implying that the cost savings tend to be higher in high-risk patients.…”

Section: Corroborating Evidence From Around the Worldmentioning

confidence: 99%

Costs associated with transradial access and same-day discharge after percutaneous coronary intervention: a systematic review and meta-analysis

Kulkarni¹,

Thangam²,

Liu³

et al. 2021

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Transradial access for PCI (TRI) along with same day discharge (SDD) is associated with varying estimates of cost savings depending on the population studied, the clinical scenario and application to low-risk vs high-risk patients. A summary estimate of the true cost savings of TRI and SDD are unknown. We searched the PubMed, EMBASE®, CINAHL® and Google Scholar® databases for published studies on hospitalization costs of TRI and SDD. Primary outcome of interest in all included studies was the cost saving with TRI (or SDD), inflationcorrected US$ 2018 values using the medical consumer price index. For meta-analytic synthesis, we used Hedges' summary estimate (g) in a random-effects framework of the DerSimonian and Laird model, with inverse variance weights. Heterogeneity was quantified using the I 2 statistic. The cost savings of TRI from four US studies of 349,757 patients reported a consistent and significant cost saving associated with TRI after accounting for currency inflation, of US$ 992

show abstract

“…Thoroughly designed prospective, randomized trial focusing on following issues: multicentricity, pharmacologic approach, thrombus removal and cost-effectiveness analysis would provide the best answer to the aforementioned doubts. Multicentricity is important for significant variability in costs reported for interventional procedures reported by different cath labs [30]. The suggested pharmacologic approach should comprise unfractionated heparin, double bolus of eptifibatide and ticagrelor.…”

Section: Future Perspectivementioning

confidence: 99%

Cost assessment of treatment of acute myocardial infarction and angiographically visible coronary thrombus

et al. 2018

View full text Add to dashboard Cite

show abstract

Cath lab costs in patients undergoing percutaneous coronary angioplasty — detailed analysis of consecutive procedures

Cited by 6 publications

References 22 publications

Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years

Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years

Costs associated with transradial access and same-day discharge after percutaneous coronary intervention: a systematic review and meta-analysis

Cost assessment of treatment of acute myocardial infarction and angiographically visible coronary thrombus

Contact Info

Product

Resources

About